Division of Psychosocial research and Epidemiology, Netherlands Cancer Institute, Antoni van Leeuwenhoek, Amsterdam, The Netherlands.
Division of Molecular Pathology, Netherlands Cancer Institute, Antoni van Leeuwenhoek, Amsterdam, The Netherlands.
Ann Surg. 2018 May;267(5):952-958. doi: 10.1097/SLA.0000000000002239.
To assess cause-specific mortality in women treated for ductal carcinoma in situ (DCIS).
From screening and treatment perspective, it is relevant to weigh the low breast cancer mortality after DCIS against mortality from other causes and expected mortality in the general population.
We conducted a population-based cohort study comprising 9799 Dutch women treated for primary DCIS between 1989 and 2004 and estimated standardized mortality ratios (SMRs).
After a median follow up of 9.8 years, 1429 patients had died of whom 284 caused by breast cancer (2.9% of total cohort). DCIS patients <50 years experienced higher mortality compared with women in the general population (SMR 1.7; 95% confidence interval, CI: 1.4-2.0), whereas patients >50 had significantly lower mortality (SMR 0.9; 95% CI: 0.8-0.9). Overall, the risk of dying from general diseases and cancer other than breast cancer was lower than in the general population, whereas breast cancer mortality was increased. The SMR for breast cancer decreased from 7.5 (95% CI: 5.9-9.3) to 2.8 (95% CI: 2.4-3.2) for women aged <50 and >50 years, respectively. The cumulative breast cancer mortality 10 years after DCIS was 2.3% for women <50 years and 1.4% for women >50 years treated for DCIS between 1999 and 2004.
DCIS patients >50 years had lower risk of dying from all causes combined compared with the general female population, which may reflect differences in health behavior. Women with DCIS had higher risk of dying from breast cancer than the general population, but absolute 10-year risks were low.
评估乳腺导管原位癌(DCIS)治疗后女性的特定病因死亡率。
从筛查和治疗的角度来看,权衡 DCIS 后的低乳腺癌死亡率与其他病因死亡率和一般人群预期死亡率是相关的。
我们进行了一项基于人群的队列研究,纳入了 1989 年至 2004 年期间接受原发性 DCIS 治疗的 9799 名荷兰女性,并估计了标准化死亡率比(SMR)。
在中位随访 9.8 年后,有 1429 名患者死亡,其中 284 例死于乳腺癌(占总队列的 2.9%)。<50 岁的 DCIS 患者与一般人群相比死亡率更高(SMR 1.7;95%置信区间,CI:1.4-2.0),而>50 岁的患者死亡率显著降低(SMR 0.9;95%CI:0.8-0.9)。总体而言,死于一般疾病和非乳腺癌癌症的风险低于一般人群,而乳腺癌死亡率增加。<50 岁和>50 岁的女性乳腺癌死亡率分别从 DCIS 后 7.5(95%CI:5.9-9.3)降至 2.8(95%CI:2.4-3.2)。对于 1999 年至 2004 年期间接受 DCIS 治疗的<50 岁和>50 岁的女性,10 年后的累积乳腺癌死亡率分别为 2.3%和 1.4%。
与一般女性人群相比,>50 岁的 DCIS 患者死于各种原因的风险较低,这可能反映了健康行为的差异。患有 DCIS 的女性死于乳腺癌的风险高于一般人群,但绝对 10 年风险较低。